GRM2 and post-traumatic stress disorder: Highly selective mGluR2/3 agonists depress excitatory neurotransmission in the amygdala (48), suggesting that such agonists may be potentially therapeutic for PTSD patients by reducing amygdala hyperactivity (32, 49).